Other Vaccines - Benelux

Benelux

Highlights

In Benelux, the revenue in the Other Vaccines market is forecasted to reach US$545.10m in 2024.
It is expected that the revenue will exhibit an annual growth rate (CAGR 2024-2029) of 10.05%, leading to a market volume of US$880.00m by 2029.
When compared to other countries worldwide, United States is projected to generate the highest revenue of US$24.73bn in 2024.
The Benelux region has seen a surge in demand for other vaccines due to its high healthcare standards and proactive approach to public health.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Other Vaccines market in Benelux has been steadily growing in recent years.

Customer preferences: Customers in Benelux are increasingly concerned about the spread of infectious diseases and are taking preventative measures by getting vaccinated. This trend is particularly evident in the Other Vaccines market, which includes vaccines for diseases such as meningitis, pneumonia, and hepatitis B.

Trends in the market: One trend in the Other Vaccines market in Benelux is the increasing demand for combination vaccines, which offer protection against multiple diseases in a single shot. This is particularly appealing to parents who want to ensure their children are protected against a range of diseases without having to schedule multiple appointments. Another trend is the growing popularity of travel vaccines, as more people in Benelux are traveling to exotic destinations and want to protect themselves against diseases that are not common in their home country.

Local special circumstances: One factor that is driving the growth of the Other Vaccines market in Benelux is the region's high population density. This makes it easier for infectious diseases to spread, which in turn has led to greater awareness of the importance of vaccination. Additionally, the region's large number of international travelers has contributed to the demand for travel vaccines.

Underlying macroeconomic factors: The strong economy in Benelux has allowed people to prioritize their health and invest in preventative measures such as vaccination. Additionally, the region's robust healthcare system has made it easy for people to access vaccines. Finally, the government in Benelux has been proactive in promoting vaccination, which has helped to raise awareness and encourage people to get vaccinated.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.